HALO
- Halozyme Therapeutics, Inc.
()
Overview
Company Summary
Halozyme Therapeutics, Inc. (HALO) is a biotechnology company that specializes in developing and commercializing novel therapies to treat cancer and other diseases. The company focuses on creating innovative drug delivery solutions using its proprietary ENHANZE� drug delivery technology platform.
Halozyme's ENHANZE� technology is designed to improve the delivery and performance of therapeutic drugs by temporarily modifying the extracellular matrix, a non-cellular component present around cells. This technology enables drugs to be delivered more efficiently, leading to enhanced therapeutic benefits.
The company collaborates with pharmaceutical and biotechnology companies to license and utilize its ENHANZE� technology. These collaborations involve combining the partner's proprietary drug molecules with Halozyme's technology to create subcutaneous versions of their drugs. By converting intravenous therapies into subcutaneous forms, the ENHANZE� technology can potentially reduce the time and discomfort associated with traditional IV infusions, enhancing patient convenience and compliance.
Halozyme also has an active research and development pipeline, focusing on the discovery and development of novel drug candidates using its proprietary platform technologies. These technologies include enzymatic degradation and immune modulation, which offer opportunities to address unmet medical needs across various therapeutic areas.
In summary, Halozyme Therapeutics, Inc. utilizes its ENHANZE� drug delivery technology platform to enhance the delivery and efficacy of therapeutic drugs. Through collaborations with pharmaceutical partners and internal R&D efforts, Halozyme aims to advance novel therapies for the treatment of cancer and other diseases.